Alpha9 Theranostics: Funding, Investors & Team (Sep 2026)
Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.
Alpha9 Theranostics has raised $250M across 2 funding rounds on record, the most recent a Series C of $175M announced in Oct 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Alpha9 Theranostics Company Profile and Key Stats
Latest funding round on record: Oct 2024.
Alpha9 Theranostics Funding Rounds
Alpha9 Theranostics raised $75.0M in a Series B announced in Dec 2022.
1.8 years later, a Series C of $175M was announced in Oct 2024.
Alpha9 Theranostics Founders and Leadership Team
Contact details for the Alpha9 Theranostics team: 1 of 2 have an email address on file.
Start 14-day free trial →Alpha9 Theranostics Funding Compared to Other Biotechnology Startups
Alpha9 Theranostics' latest round of $175M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Alpha9 Theranostics in Biotechnology and Vancouver
Companies Similar to Alpha9 Theranostics
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
Alpha9 Theranostics Funding FAQs
What does Alpha9 Theranostics do?
Alpha-9 Theranostics is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.
How much funding has Alpha9 Theranostics raised?
Alpha9 Theranostics has raised $250M across 2 rounds on record. The most recent is a Series C of $175M announced in Oct 2024.
When did Alpha9 Theranostics last raise funding?
Alpha9 Theranostics' most recent funding round on record is a Series C of $175M, announced in Oct 2024.
Who founded Alpha9 Theranostics?
FundedIQ lists David Perrin (Founder) at Alpha9 Theranostics.
Who is the CEO of Alpha9 Theranostics?
Ian Mcbeath is listed as CEO at Alpha9 Theranostics.
Where is Alpha9 Theranostics headquartered?
Alpha9 Theranostics is based in Vancouver, British Columbia, Canada.
How many employees does Alpha9 Theranostics have?
Alpha9 Theranostics is in the 11-50 employee band.
How does Alpha9 Theranostics' funding compare to other Biotechnology startups?
Alpha9 Theranostics' latest round of $175M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Alpha9 Theranostics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Alpha9 Theranostics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.